ArticleItch (Philadelphia, Pa.)
A review of catechins and their use in atopic dermatitis.
Article in Itch (Philadelphia, Pa.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-Inflammation and Anti-Hypersensitivity Effects ofPreventive nutrition and food science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by persistent itching of the skin with its prevalence increasing in the United States. AD has a complex pathogenesis that remains to be fully resolved, though it is shown to involve immune dysregulation and skin barrier dysfunction, with multiple environmental and genetic factors implicated. The interplay between the immune system and environmental exposures can incite immune responses with the release of cytokines, IgE, eosinophils, and mast cells, which trigger symptoms of AD in susceptible patients. There are many therapies used in AD; however, the first-line treatment for flares continues to be corticosteroids. The broad range of therapies available for AD is associated with adverse effects, poor adherence, and financial burden, accentuating the need to assess alternative therapies. A promising alternative therapy is the catechin family, a group of flavonoids with a unique structure that has anti-inflammatory, antimicrobial, antioxidant, and skin barrier modulating properties. In this review, we describe the structure and related properties of catechins, their function, and how they can be utilized in the treatment of AD. Furthermore, we describe limitations associated with the use of catechins and the necessity of further research in this area. The function of catechins has been widely shown to modulate the inflammatory pathway and skin barrier dysfunction that have been implicated in AD and reduce symptoms. While catechins can mitigate symptoms and reduce associated inflammatory markers, further research is required to develop a therapy that retains the beneficial functions of catechins without increasing cytotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.